Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 6,164 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 6,164 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total value of $203,473.64. Following the transaction, the insider owned 47,484 shares in the company, valued at approximately $1,567,446.84. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total value of $209,539.24.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.99, for a total value of $43,815.39.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $33.91 on Friday. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22. The company’s 50 day moving average price is $32.60 and its 200-day moving average price is $29.93. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 50.61 and a beta of 1.07.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics in the fourth quarter worth about $26,000. Harbour Investments Inc. boosted its position in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares in the last quarter. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the 3rd quarter worth approximately $41,000. BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of analyst reports. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective on the stock. HC Wainwright raised their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. UBS Group set a $50.00 price target on Stoke Therapeutics in a research report on Monday, December 15th. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Finally, Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.83.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.